TY - JOUR
T1 - Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum
AU - Allison, Samantha L.
AU - Rodebaugh, Thomas L.
AU - Johnston, Chiharu
AU - Fagan, Anne M.
AU - Morris, John C.
AU - Head, Denise
N1 - Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press. All rights reserved.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Objective: There remains a need for a non-invasive and cost-effective screening measure that could be administered prior to the provision of a lumbar puncture or positron emission tomography scan for the detection of preclinical Alzheimer disease (AD). Previous findings suggest that a hippocampally-based spatial navigation task may be effective for screening individuals for the preclinical AD continuum (i.e., low cerebrospinal fluid (CSF) Aβ42). Unfortunately, this task took 1.5-2 hours to administer, which would be time-prohibitive in a clinical setting. Therefore, the goal of this study was to compare psychometric properties of six spatial navigation-related tasks in order to take the next steps in developing a clinically appropriate screening measure. Methods: Psychometric properties (i.e., reliability, diagnostic accuracy, validity) of a modified version of the cognitive mapping task, two binding tasks, a visual perspective taking task, and self- and informant report versions of a questionnaire were examined in a sample of 91 clinically normal (CN) individuals. CSF Aβ42 and ptau181 were available for 30 individuals. Results: The learning phase of the cognitive mapping task and the self-report questionnaire were sensitive to identifying individuals in the preclinical AD continuum (93% and 87% sensitivity, 60% and 67% specificity, respectively). These two measures also demonstrated good test-retest stability (intraclass correlation coefficients =. 719 and. 838, respectively) and internal consistency (Cronbach's αs =. 825 and. 965, respectively). Conclusions: These findings suggest that a self-report questionnaire and aspects of a cognitive mapping task may be particularly appropriate for development as screening tools for identifying individuals in the preclinical AD continuum.
AB - Objective: There remains a need for a non-invasive and cost-effective screening measure that could be administered prior to the provision of a lumbar puncture or positron emission tomography scan for the detection of preclinical Alzheimer disease (AD). Previous findings suggest that a hippocampally-based spatial navigation task may be effective for screening individuals for the preclinical AD continuum (i.e., low cerebrospinal fluid (CSF) Aβ42). Unfortunately, this task took 1.5-2 hours to administer, which would be time-prohibitive in a clinical setting. Therefore, the goal of this study was to compare psychometric properties of six spatial navigation-related tasks in order to take the next steps in developing a clinically appropriate screening measure. Methods: Psychometric properties (i.e., reliability, diagnostic accuracy, validity) of a modified version of the cognitive mapping task, two binding tasks, a visual perspective taking task, and self- and informant report versions of a questionnaire were examined in a sample of 91 clinically normal (CN) individuals. CSF Aβ42 and ptau181 were available for 30 individuals. Results: The learning phase of the cognitive mapping task and the self-report questionnaire were sensitive to identifying individuals in the preclinical AD continuum (93% and 87% sensitivity, 60% and 67% specificity, respectively). These two measures also demonstrated good test-retest stability (intraclass correlation coefficients =. 719 and. 838, respectively) and internal consistency (Cronbach's αs =. 825 and. 965, respectively). Conclusions: These findings suggest that a self-report questionnaire and aspects of a cognitive mapping task may be particularly appropriate for development as screening tools for identifying individuals in the preclinical AD continuum.
KW - amyloid
KW - cognition
KW - hippocampus
KW - ptau
KW - reliability
KW - validity
UR - http://www.scopus.com/inward/record.url?scp=85074745155&partnerID=8YFLogxK
U2 - 10.1093/arclin/acz019
DO - 10.1093/arclin/acz019
M3 - Article
C2 - 31197326
AN - SCOPUS:85074745155
SN - 0887-6177
VL - 34
SP - 1138
EP - 1155
JO - Archives of Clinical Neuropsychology
JF - Archives of Clinical Neuropsychology
IS - 7
ER -